Tenax Therapeutics Inc
TENX
NASDAQ
Biotechnology
$1.80
USD
-0.03 (-1.64%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $64.93M
Volume 5.8M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-64.86M
TTM
-106.0%
YoY
Operating Cash Flow
$-46.03M
TTM
-132.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.7 | 6.5 | 5.9 | 5.0 | 5.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 11.8 | 16.8 | 16.4 | 16.6 | 18.8 |
Operating Income | -11.8 | -16.8 | -16.4 | -16.6 | -18.8 |
EBITDA | -11.8 | -16.8 | -16.4 | -16.6 | -18.8 |
Other Income / Expense | -0.0 | -0.0 | -0.0 | -0.0 | 0.0 |
Total Other Income / Expense | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 |
Income Before Income Taxes | -10.8 | -15.8 | -15.5 | -15.7 | -17.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -10.8 | -15.8 | -15.5 | -15.7 | -17.8 |
Consolidated Net Income / Loss | -10.8 | -15.8 | -15.5 | -15.7 | -17.8 |
Net Income Attributable to Common Shareholders | -10.8 | -15.8 | -15.5 | -15.7 | -17.8 |
Basic EPS | -$0.27 | -$0.40 | -$0.38 | -$0.35 | -$0.35 |
Diluted EPS | -$0.27 | -$0.40 | -$0.38 | -$0.35 | -$0.35 |
Basic Shares Outstanding | 39.6M | 39.7M | 41.0M | 45.2M | 50.9M |
Diluted Shares Outstanding | 39.6M | 39.7M | 41.0M | 45.2M | 50.9M |